RPL3L and atherosclerosis: Pediatric patients with RPL3L mutations developed severe DCM in the absence of comorbidities such as atherosclerosis, hypertension, myocardial ischemia or diabetes mellitus [1], highlighting a direct connection of RPL3L with DCM and immune-mediated inflammation.